Research
Competition and Biosimilar Products--In Reply
Drs Frankel and McKay first note that the FDA is able to ensure biosimilar and reference biologic quality through prerelease specifications.
How Much Donor Financing for Health is Channeled to Global Versus Country-Specific Aid Functions?
The slow global response to the Ebola crisis in west Africa suggests that important gaps exist in donor financing for key global functions, such as support for health research and development for dise
Patents, Monopoly Power, and the Pricing of Pharmaceuticals in Low-income Nations
Research: Perhaps Market Forces Do Work in Health Care After All
Economists’ Declaration on Universal Health Coverage
The author offers insights on a sustainable development agenda launched by the United Nations to call on global policy makers to prioritize a pro-poor pathway to universal health coverage as an essent
Medicare Advantage: What Explains Its Robust Health?
The Medicare Advantage (MA) program continues to grow and thrive, despite plan payment cuts imposed through the Affordable Care Act.
Characterization of Remitting and Relapsing Hyperglycemia in Post-Renal-Transplant Recipients
Outcomes of Basic Versus Advanced Life Support for Out-of-Hospital Medical Emergencies
Most Medicare patients seeking emergency medical transport are treated by ambulance providers trained in advanced life support (ALS).
What Determines End-of-Life Assets? A Retrospective View
We consider assets when individuals were last observed prior to death in the Health and Retirement Study (HRS) and trace assets backwards to the age when these individuals were first observed.
Get smart & reliable public policy insights right in your inbox.